Enzo Biochem (ENZ)
(Delayed Data from NYSE)
$1.18 USD
+0.04 (3.51%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.12 -0.06 (-5.08%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.18 USD
+0.04 (3.51%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.12 -0.06 (-5.08%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Zacks Initiates Coverage of Enzo Biochem With Neutral Recommendation
by Debanjana Dey
Discover why Zacks rates Enzo Biochem as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore ENZ's notable revenue growth and financial health amid market challenges.
Enzo Biochem (ENZ) Q3 Earnings Improve Y/Y, Gross Margin Up
by Zacks Equity Research
Enzo Biochem's (ENZ) overall topline benefits from revenue growth in the majority of its geographic regions.
Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern
by Zacks Equity Research
Geron Corporation's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.
Pacira Pharmaceuticals Focuses on Exparel's Label Expansion
by Zacks Equity Research
Pacira Pharmaceuticals, Inc. (PCRX) is making efforts to expand its flagship product, Exparel, which was launched in 2012.
Nektar's (NKTR) Shares Fall Post Wider Q2 Loss, Revenues Lag
by Zacks Equity Research
Nektar (NKTR) reports wider-than-expected loss with revenues falling shy of estimates. However, the top line rises year over year, courtesy an increase in product sales and royalty revenues.
Novo Nordisk (NVO) Beats on Q2 Earnings, Revenues Miss
by Zacks Equity Research
Novo Nordisk A/S (NVO) beat earnings estimates but missed revenue estimates in Q2. Robust performance for Victoza and Tresiba will drive growth.
Intrexon (XON) Q2 Loss Narrower than Expected, Revenues Miss
by Zacks Equity Research
Intrexon Corporation (XON) incurred narrower than expected loss and missed revenue estimates in Q2.
Catalyst (CPRX) Posts Narrower than Expected Loss in Q2
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) reported narrower than expected loss in Q2 and is focused on the development of its pipeline candidate Firdapse.
Perrigo (PRGO) Q2 Earnings & Sales Top, 2017 View Raised
by Zacks Equity Research
Perrigo (PRGO) posts better-than-expected results with revenue beating estimates. The company also ups its earnings outlook, courtesy a continued positive execution across all business segments.
The Medicines Company (MDCO) Q2 Loss Widens, Revenues Miss
by Zacks Equity Research
The Medicines Company (MDCO) reports wider-than-expected loss with revenues missing estimates. The top line also decreases year over year due to low Angiomax sales.
BioDelivery (BDSI) Q2 Loss Wider than Expected, Stock Falls
by Zacks Equity Research
BioDelivery Sciences International (BDSI) reported wider-than-expected Q2 loss. However, Belbuca registered record sales for the second consecutive quarter.
Merrimack (MACK) Q2 Loss Wider than Expected, Stock Falls
by Zacks Equity Research
Merrimack Pharmaceuticals (MACK) reported wider-than-expected loss in the second quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.
Jazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact
by Zacks Equity Research
Jazz Pharma's (JAZZ) earnings and revenues miss estimates. However, the top line rises year over year owing to higher sales of the company's marketed drug, Xyrem.
Orexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress
by Zacks Equity Research
Orexigen Therapeutics (OREX) reported adjusted loss of $1.82 per share in the second quarter of 2017, which was narrower than the Zacks Consensus Estimate. The company is focused on increasing the reach of Contrave.
Agios (AGIO) Q2 Loss Wider than Expected, Revenues Up Y/Y
by Zacks Equity Research
Agios (AGIO) reports wider-than-expected loss with revenues marginally lagging estimates. However, the top line improves year over year, thanks to reimbursement received from Celgene.
Endocyte (ECYT) Stock Up Despite Wider-than-Expected Q2 Loss
by Zacks Equity Research
Endocyte (ECYT) second quarter loss was wider than expected. The company has announced restructuring initiatives to shift its pipeline focus to CAR-T cell platform.
Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update
by Zacks Equity Research
Achillion Pharmaceuticals (ACHN) second-quarter loss was in-line with estimates. The company's shares surged almost 28% in after-market trading on positive pipeline results.
PDL BioPharma (PDLI) Q2 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings surpass expectations. Revenues also significantly increase year over year, thanks to a rise in fair value of the Depomed royalty asset.
Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2
by Zacks Equity Research
Epizyme, Inc. (EPZM) posted narrower-than-expected loss in Q2 as the company focuses on the development of tazemetostat.
Juno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass
by Zacks Equity Research
Juno Therapeutics (JUNO) reports wider-than-expected loss but revenues beat estimates. However, revenue decreased year-over-year.
Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
Agenus Inc. (AGEN) witnesses narrower-than-expected loss and also misses revenue estimates. However, the company is progressing well with the candidates in its pipeline in Q2.
AMAG Pharma (AMAG) Incurs Narrower-than-Expected Loss in Q2
by Zacks Equity Research
AMAG Pharmaceuticals, Inc. (AMAG) posted narrower-than-expected loss and slightly beat revenue estimates in Q2.
Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Conatus (CNAT) reports wider-than-expected loss in Q2. However, revenue beat estimates, courtesy higher collaboration benefits.
Pacira (PCRX) Q2 Loss Wider than Expected, Revenues Miss
by Zacks Equity Research
Pacira Pharmaceuticals, Inc. (PCRX) remains confident about the prospects of its lead drug Exparel in Q2.
Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Corcept Therapeutics Incorporated's (CORT) top line was driven by the strong sales of its only market drug Korlym. Thus the company raised its 2017 revenue guidance.